Fundraising Fox
Novoron
San Diego, US · Founded 2014 · Delaware corporation · 17 employees on LinkedIn · 2 known investors
Find your way into Novoron
Sign up to see every warm intro you have to Novoron
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Novoron team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Novoron develops lipoprotein-receptor small molecule therapies aimed at repairing damage and degeneration of the brain and spinal cord, including treatments for proteinopathies and neuroregeneration following traumatic injury. The company focuses on drug discovery for neurological conditions such as neurodegeneration and cognitive decline.
Founders & leadership
Novoron was founded in 2014 by Travis Stiles and Shawn Gahr.
TS
Travis StilesCo-founder · President and CEOTravis Stiles is CEO and co-founder of Novoron, which develops small molecule therapies targeting lipoprotein receptors for neurological conditions including neurodegeneration and traumatic spinal cord injury. He has a background in science and has worked on drug discovery for neurological disorders.
DW
David WeinerExecutive Chairman
RM
Ryan McMillianCFO & Financial Strategy
Board
MG
Investors · 2
Two Bear Capitallisted by Two Bear CapitalWhitefish · $3M – $10M
How we know: Two Bear Capital's portfolio page · board seat on SEC Form D · funding news · press coverage · the VCSheet dataset · Not right? Tell us
Backstage CapitalreportedLos Angeles · $50K
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$15.2M disclosed across 2 rounds · 2021–2022
▶$12.1MraisedDec 2022 · 2 investors · BiotechnologyRule 506(b)
▶$12.1MraisedDec 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Travis StilesExecutive Officer, Director
- Michael GoguenDirector
- Shawn GahrExecutive Officer, Director
- Offering amount
- $12.1M
- Amount sold
- $12.1M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedJul 2021 · 2 investors · BiotechnologyRule 506(b)
▶$3MraisedJul 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Travis StilesExecutive Officer, Director
- Shawn GahrDirector
- Michael GoguenDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
LongeveronLongeveron is a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions affecting children and the elderly. Its investigational candidate is being evaluated for indications including Hypoplastic Left Heart Syndrome, Pediatric Dilated Cardiomyopathy, Alzheimer's Disease, and age-related frailty.
GeronGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
PharmaronPharmaron is a contract research and manufacturing organization providing drug development and manufacturing services to pharmaceutical and biotech companies.
InGeneronInGeneron develops regenerative cell therapies that use a patient's adult stem cells and other regenerative cells harvested from fat or bone marrow to treat specific injuries. The company focuses on developing FDA-approved therapies through clinical trials and research in the regenerative medicine field.
ImunonImunon develops DNA-based immunology technologies designed to treat difficult-to-treat conditions including ovarian cancer and infectious diseases. The company's platforms instruct the immune system to generate targeted therapeutic responses.
Companies working in the same space as Novoron.
In the news
Frequently asked questions
- What does Novoron do?
- Novoron develops lipoprotein-receptor small molecule therapies aimed at repairing damage and degeneration of the brain and spinal cord, including treatments for proteinopathies and neuroregeneration following traumatic injury. The company focuses on drug discovery for neurological conditions such as neurodegeneration and cognitive decline.
- Who founded Novoron?
- Novoron was founded by Travis Stiles, Shawn Gahr in 2014.
- Who are Novoron's investors?
- Novoron's investors include Two Bear Capital, Backstage Capital.
- How much funding has Novoron raised?
- Novoron has disclosed $15.2M raised across 2 rounds.
- Where is Novoron headquartered?
- Novoron is headquartered in San Diego, US.